to purchase up to 1,500,000 shares of Incyte’s common stock at a price of $88.88 per share in cash. TRC's offer price …
Unfortunately, Incyte posted a loss on the year despite making an incredibly recovery from its February lows. Looking ahead, one analyst sees solid upside for this stock. Credit Suisse has an Outperform rating with a $137 price target, …
Exelixis (NASDAQ: EXEL) is without question one of the hottest biotech stocks on the market. We're talking about a stock that has more than tripled in value in just the last 12 months and has soared over 70% so far this year. Exelixis is, …
NWI7mon
For a hedged play on Incyte (INCY) MarketIntelligenceCenter.com’s patented trade-picking algorithms selected a Feb 16, 2018 $100 covered call for a net debit in the $94.89 area. That is also the break-even stock price for the covered call. …
This suggests that analysts have very recently bumped up their estimates for INCY, giving the stock a Zacks Earnings ESP of +40.11% heading into earnings season. Why is this Important? A positive reading for the Zacks Earnings ESP …
Incyte Corporation INCY reported third-quarter earnings of 11 cents (including the impact of a change in fair value of acquisition-related contingent consideration and unrealized gain on long term investment). The Zacks Consensus …
Jan 31 (Reuters) - Incyte Corp: * SYROS PHARMACEUTICALS -‍ ON JAN 31, ENTERED AMENDMENT NO. 1 TO STOCK PURCHASE AGREEMENT WITH INCYTE TO FACILITATE PRIVATE PLACEMENT - SEC FILING * SYROS …
Incyte Corp., the $31 billion Alapocas biotech that recently joined the Standard and Poor's 500 index, saw its stock soar to an all-time high of $151.88 on Tuesday as rumors swirled over a potential deal with the struggling California …